Orkla ASA (ORK) Earnings Call Transcript & Summary
November 6, 2026
Earnings Call Speaker Segments
Annie Bersagel
executiveGood morning, everyone, and welcome as we present Orkla's results for the third quarter. I'm Annie Bersagel, serving as Head of Investor Relations and Communications. First up is a presentation by our President and CEO, Nils Selte, who'll walk you through an overview of the quarter. Following him, our CFO, Arve Regland, will go into greater detail on the financials as well as each of the portfolio companies. Nils will then wrap things up with some closing remarks. A quick note on how the Q&A will work: we'll start with a video Q&A featuring analysts. Those questions come first, though you're welcome to send questions in through the web at any point, and we'll get to those later on. So, with that covered, Nils, over to you.
Nils Selte
executiveThank you, Annie, and good morning to all of you. As Annie mentioned, I'll walk through the quarter's highlights, and after that Arve will give you more detail. I'm happy to say Orkla delivered a strong quarter despite a challenging geopolitical backdrop. Performance has fluctuated over the course of the year, but the overall picture is positive, with volume growth of 1.5% year to date. We're seeing good progress on profitability across the portfolio, and the companies are handling a difficult input cost situation well. Let's go into some of the third-quarter details. Organic growth came in at 3.1%, with positive contributions spread broadly across a majority of the portfolio companies. Underlying EBIT adjusted rose by 8.1%. That positive development also helped lift adjusted earnings per share by 4.9%, which came to NOK 1.94. Volume mix accounted for a significant share of the organic growth, contributing 2.7% this quarter. Most portfolio companies posted positive volume growth, and growth was especially strong at Orkla Snacks, where volume mix growth was 11.2%, driven mainly by the confectionery category. Orkla Home & Personal Care also delivered double-digit volume growth this quarter. Even in a challenging environment, Jotun kept delivering growth in underlying operating profit.
Nils Selte
executiveIt's good to see that, among our 9 consolidated portfolio companies, 8 posted improvements in underlying EBIT adjusted for the quarter. And looking at the big picture, volume mix served as a major driver of EBIT adjusted growth throughout those consolidated companies. Within that group, Orkla Snacks once again stands out on the positive side, with volume-driven underlying EBIT growth of 16%. The rolling 12-month EBIT margin came in slightly better than in the previous quarter. Input price trends differed from one part of the portfolio to another. Costs for marine products, meat and packaging were higher than a year ago. Meanwhile, costs for other input factors, including cocoa and dairy, went down. The price outlook is still fragmented across the various input factors. We anticipate a modest rise in prices in 2027. That said, the outlook continues to be uncertain. As we always do, we are watching the situation closely on an ongoing basis. This marks our final quarterly presentation ahead of our Capital Markets Day on December 1. We remain on track to close out 2026 within the mid- to upper range of our targets of 8% to 10% annual growth in underlying EBIT adjusted. The EBIT margin is likewise tracking inside the target range. Return on capital employed has risen considerably over the strategy period, though we do not anticipate hitting 13%.
Nils Selte
executiveSo with that, I'll turn things over to Arve.
Arve Regland
executiveThanks, Nils, and good morning. So let's begin with the income statement. We'll offer a few remarks on some of the other items. To start, operating revenues: reported operating revenues fell 2% in the quarter, which mirrors negative currency translation effects of 6.4%. Reported EBIT adjusted rose 2%, though currency effects also weighed on it. Other income and expenses came to a net cost of NOK 490 million. That's mainly tied to write-downs of goodwill and trademarks at Healthspan within Orkla Health, plus a loss on the sale of Eisunion in Orkla Food Ingredients. Within discontinued operations, we booked a gain from reversal of provisions linked to the sale of Sapa back in 2017. And as Nils noted, earnings per share adjusted were up 4.9% this quarter. Cash flow from operations reached NOK 4.4 billion year-to-date, roughly NOK 400 million below last year. About half of that decline stemmed from working capital. That mirrors both higher receivables following sales growth and a temporary inventory buildup ahead of an ERP implementation in Orkla Foods Norway. And cash flow before capital allocation was NOK 3.9 billion year-to-date. So moving on to capital allocation and leverage. In the quarter, share buybacks totaled approximately NOK 1 billion, which covers both the completion of the NOK 4 billion share buyback program announced in November last year and the new NOK 4 billion share buyback program we announced in September.
Arve Regland
executiveCapital spending rose by NOK 260 million in the quarter, with the bulk of it in Orkla Snacks and Orkla Food Ingredients. Acquisitions and divestments had a net cash flow impact of roughly NOK 2.9 billion for the quarter, the biggest piece being the purchase of The European Candy Group. Leverage stood at 2.1x EBITDA when the quarter closed. Now let's turn to the portfolio of companies in more detail. We'll begin, as always, with Jotun, whose underlying revenue was up 13% in the third quarter across segments and markets, lifted by both volume and price. Gross margins came down since the price hikes did not entirely cover higher raw material costs. Underlying operating profit increased 1.3%. Reported operating profit dropped 5.1%, reflecting adverse currency translation effects. Orkla's share of profit from Jotun declined 6.6% to NOK 563 million. Jotun's outlook is still uncertain because of the conflict in the Middle East. Demand in the more affected markets has held up, yet the conflict brings uncertainty regarding supply, logistics and business conditions. Margin pressure is anticipated to persist over the coming quarters. At Orkla Foods, organic revenue increased 2.4%, with 1.5% of that coming from volume mix.
Arve Regland
executiveOur growth platforms generated volume mix growth of 5.3%, with every market growing. We also saw a favorable impact from the comparison against last year's ERP difficulties in the Czech Republic. Input costs rose somewhat, with larger increases for mackerel and packaging. Underlying EBIT adjusted was up 7.6%, supported by revenue growth and ongoing cost discipline. Orkla Snacks posted organic growth of 5.6%, and volume mix delivered a record-high 11%. Lower prices, chiefly in chocolate products, partly offset that organic growth. All three categories — confectionery, snacks and biscuits — posted volume mix growth. Confectionery made the biggest contribution, with 4 main drivers. Bubs kept growing in the U.S. and throughout the Nordics, with additional expansion in Finland and launches in Estonia and Latvia. Second, Smash! also kept growing, including from its launch in Latvia. Third, chocolate volumes are still recovering, helped by lower prices. And finally, Christmas sales occurring earlier than last year gave volumes an extra boost in the third quarter. Underlying EBIT adjusted rose by 16%, driven by higher volumes but partly offset by increased advertising spend and SG&A costs. Orkla Home & Care -- Home & Personal Care delivered organic growth of 10%, coming almost entirely from volume mix.
Arve Regland
executiveNorway, Sweden, and contract manufacturing all saw higher volumes, helped by increased campaign activity. Some of that growth comes from favorable phasing effects that moved sales into the third quarter—partly out of the second quarter and partly out of the fourth. Underlying EBIT adjusted rose 8.7%. Orkla Food Ingredients developed more quietly, with organic revenue growth of 0.7%. Prices came down, reflecting lower input costs across several markets and categories. Volume mix grew in bakery and sweet, but in plant-based, lower volumes and unfavorable mix effects hurt both overall volume mix and EBIT development. Underlying adjusted EBIT fell 2%. Higher operating costs more than outweighed the volume growth. As we mentioned last quarter, Orkla Food Ingredients is taking steps to reduce its cost base, though the effect will be limited this year. Organic growth at Orkla Health was flat in the quarter. Price increases in most categories were offset by lower volume mix. The bulk of the decline came from food supplements, where price increases weighed on volumes. Orkla Health and Functional Personal Care contributed positively to revenue and EBIT growth alike. Underlying EBIT adjusted was up 6.1%. Pricing and mix raised the contribution margin, which more than offset higher operating costs.
Arve Regland
executiveAs we said before, we still anticipate modest profitability at Orkla Health over the next few quarters. Orkla will share further strategy details at the Capital Markets Day. At Orkla India, organic growth reached 19%, mainly from pricing that offset substantial inflation in key raw materials, while volume growth added 2.9% as well. Government grants gave a net positive delta of roughly NOK 8 million during the quarter, and excluding that, organic growth came to 18%. Underlying EBIT adjusted growth was 7%, though it was flat once the grants' effect is excluded. Consumer sales at the European Pizza Company rose 9.7%, with gains across every business. Organic revenue fell 1.9%. As was the case last quarter, this stems chiefly from reduced third-party sales within Kotipizza's wholesale operation. Underlying EBIT adjusted was up 5.4%, helped by stronger consumer sales and favorable mix effects. Orkla House Care and Health and Sports Nutrition Group both kept progressing well during the quarter and added to Orkla's organic revenue growth and underlying EBIT growth. With that, Nils, I'll return it to you for the closing remarks.
Nils Selte
executiveThanks, Arve. Back in 2023, I laid out 3 strategic priorities: drive organic value, reduce complexity, and carry out structural changes or transactions that add value. This quarter, our progress came from driving organic value, and I'm pleased with the progress made. At the Capital Markets Day in a few weeks, I'll review the full strategy period and present priorities and financial targets for the next 4 years. With that, we're now ready to begin the Q&A.
Annie Bersagel
executiveThanks for joining us again. We're set to move into the Q&A portion now. <<operator_script>> And it appears the first one up comes from Ole Martin Westgaard at DNB Carnegie.
Ole Martin Westgaard
analystOn volume growth for this quarter, we saw a clear step-up versus the second quarter. That said, you also point out that some promotion phasing moving out of Q4 helped us, and Snacks had some Christmas phasing as well. Could you put a number on how much that affected organic volume growth at the group level? And what should we expect for that in Q4?
Nils Selte
executiveAs you're aware, we don't provide guidance for Q4. What I mentioned during the presentation, though, is that when you look at the year-to-date figures and the growth — volume growth year-to-date at 1.5% — we believe that's roughly an accurate picture, or view, of how the business is performing underneath at the moment.
Ole Martin Westgaard
analystRight. And then regarding snacks, just to follow up on that point. Is there anything you can share about the amount Bubs added to organic growth in Snacks during Q3?
Nils Selte
executiveI can't share exact figures, unfortunately. What we're seeing with Bubs, though, is growth in every market it operates in. So it's expanding nicely in the Nordics, in the Baltics, and in the U.S. as well. Solid results everywhere for Bubs.
Ole Martin Westgaard
analystThen moving to costs—you mention increased energy, packaging, freight, and raw material expenses in both Foods and Snacks as well as Food Ingredients. Has that already shown up in Q3, or will it pick up speed as we head into Q4?
Nils Selte
executiveYou can see this in the Q3 results too. And based on the picture today, we expect it to carry on in Q4 and in the quarters ahead. But of course, a lot hinges on how things stand in the Middle East. Still, as things stand right now, that's the picture we've seen, and we expect to keep seeing it as we move forward.
Ole Martin Westgaard
analystAnd then one final item about costs. Regarding marketing spending during this quarter, how did it compare with Q3 of last year? Did it stay stable? Or how has marketing spend trended through this year so far?
Nils Selte
executiveWe saw a slight uptick in the quarter versus last year.
Annie Bersagel
executiveOur next question seems to come from Andrei Condrea at UBS.
Andrei Condrea
analystIf we return to volume growth, especially within Foods, we clearly observed a solid step-up there. Could you talk about what has changed in your underlying markets? And whether that performance got somewhat flatted by any small one-offs apart from the Czech ERP implementation?
Nils Selte
executiveI believe the volume in Foods was, as you mentioned, impacted by the ERP implementation in the Czech Republic. So that's been addressed to some degree in the presentation. But apart from that, we're seeing solid growth in Sweden, as communicated. We're seeing weaker performance in Vietnam. And what we're observing across the board, in every market where Orkla Foods operates, is that the prioritized categories delivered fantastic growth this quarter. Beyond that, we aren't being specific on other items, or more — we'd prefer not to get more precise than that at the moment, actually.
Andrei Condrea
analystGot it. And suppose we were to move into India — clearly, on pricing, there’s meaningful acceleration in Q3 compared with Q2. You noted that input cost inflation is what’s driving it. Looking forward, do you see the possibility that it picks up even more? And on the other side, could there be a risk that price elasticities rise? That question also applies to the rest of the group — just trying to see where inflation stands at the moment.
Nils Selte
executiveSo, looking at India during the third quarter, input prices saw high — extremely high — inflation. That's reflected in the numbers too. As usual, I'd say we don't give precise guidance on the various input factors. It would make a lot of sense for you to watch the call they held last — or yesterday morning. That probably can shed light on things from that angle. But we're watching the situation closely alongside the team in India. And — yet what I find encouraging is that they're able to pass price through to the market on the higher input prices we're seeing right now. Anything to add to that?
Arve Regland
executiveBroadly speaking, I'd say the Indian operation is hit by unusual kinds of input costs — raw materials. That's something more specific to that market, and it's extremely volatile. For the remainder of the group, it's broader, as you mentioned: over the past 2 quarters, freight, packaging, energy — those sorts of costs that flow through every one of the portfolio companies and, on top of that, impact the overall business.
Annie Bersagel
executiveI believe the next question comes from Petter Nystrom at ABG.
Petter Nystrøm
analystI have two questions, and I'll take them one at a time. Let me start with Jotun. You mentioned pressure on margins. Now you're saying raw material costs are beginning to help—or beginning to affect—the margin, with more to come. Does that mean we should anticipate further margin pressure as we head into Q4 and '27?
Nils Selte
executivePetter, this matches what you mentioned over the past couple of quarters — input costs for Jotun began rising sharply in the market after the Middle East conflict kicked off earlier this year. We had anticipated that this would steadily affect margins across the year. We saw that play out in Q2, and we expect this picture to persist going forward. As for the magnitude, giving a precise answer is very difficult. But it aligns with what we've said: the impact on the numbers comes with some lag effects, we see it in Q2, and we expect it to carry on in the coming quarters as well.
Petter Nystrøm
analystGreat. One last question about Orkla Food Ingredients and the turnaround there. Are there any other benefits, so to speak, that you're seeing from the cost measures? And when would any meaningful impact start to show up? Should we expect that in the first half of '27, or is the second half of '27 more likely?
Nils Selte
executiveTo start with, Marianne Kirkegaard is right now serving as the acting CEO of the company. Within Orkla Food Ingredients, she has launched many different kinds of projects. Those are in progress. We don't anticipate seeing anything during this current year, since these are longer processes. However, you should see gradual effects from these initiatives throughout 2027.
Annie Bersagel
executiveMoving on, we have Hakon Fuglu from SEB.
Håkon Fuglu
analystWould you be able to walk us through how the stronger Norwegian krone affects your EBIT margin and your input costs a bit more? And how should we think about the lag effects there?
Arve Regland
executiveSo obviously, that helps — especially for the Norwegian business. Still, next to the negative effects from currency translation, the impact is considerably smaller. Even so, there are some benefits, mainly on the margin side for the Norwegian business. But we haven't pinned down exactly how large that will be — we aren't precise about the amount. And looking ahead, it's very difficult to quantify those effects going forward as well, when it comes to input costs.
Annie Bersagel
executiveWe’ve got what appears to be one more question here — let me check — yes, it’s from Ole Martin Westgaard.
Ole Martin Westgaard
analystYeah, I was just hoping you might give a bit of color on what you plan to guide toward at your Capital Markets Day — I mean, will we still get an underlying EBIT growth figure? Or are you referring to adjusted margin return on capital, that sort of framework we ought to expect at this Capital Markets Day, or any color at all would be interesting?
Nils Selte
executiveMy take is that you should hold off a bit there, Ole Martin. The Capital Markets Day is only a few weeks away. So we'll keep you wondering until then, and you can get your answers by following up at the Capital Markets Day.
Annie Bersagel
executiveThat appears to be the final question from the video. Moving on to the web questions, the first one comes from Robin Scott. Has Orkla discussed a quarterly payout as a way to boost interest in the stock?
Nils Selte
executiveThe topic has come up, though the Board is the one who will make that call. I believe it will keep being talked about. Should there be anything to share on that front, we'll return to you with it. For the time being, however, we're staying with an annual dividend.
Annie Bersagel
executiveVirag <<inaudible>> from Nordea has the second question. What's your take on how many portfolio companies you hold right now? That figure sits above the 7 to 9 target range you've stated. Should we expect any divestments in the near term?
Nils Selte
executiveRight now, Orkla has 10 portfolio companies. At the Capital Markets Day, I believe we gave guidance of 7 to 9 — that was an ambition. That said, we won't be guiding the market on any M&A activity. So we'll simply announce something once it has happened. From that perspective, we won't offer any further comments on it.
Annie Bersagel
executiveLooks like that was the final question. So, before we wrap up, I want to remind everyone that our Capital Markets Day takes place on the 1st of December, and fourth quarter results will be reported on February 10. Thanks once more for being with us, and please enjoy the rest of your day.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Orkla ASA transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Orkla ASA earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Orkla ASA or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.